Vaxart, Inc. develops oral recombinant pill vaccines based on a proprietary delivery platform. The clinical-stage biotechnology company’s programs include vaccine candidates for coronavirus, norovirus and influenza, as well as a therapeutic human papillomavirus vaccine as its first immune-oncology indication. Its pill-based vaccines are designed for oral administration, storage and shipping without refrigeration, and avoidance of needle-stick risk.
Vaxart news centers on clinical data and scientific publications, business updates, financial results, financing arrangements, collaborations, intellectual property around adenovirus and TLR3 agonist oral vaccination technology, and governance changes as the company advances its oral vaccine pipeline.
Vaxart (OTCQX: VXRT) reached a cooperation agreement with a stockholder group, resolving the proxy contest tied to its 2026 Annual Meeting. The stockholder group will withdraw three director nominations.
Vaxart will search within 90 days post-meeting for a mutually agreed independent director and will form new Stockholder Engagement and Clinical and Regulatory Affairs Board committees, refresh committee chairs, and adopt director stock ownership and resignation policies.
Summary not available.
Vaxart (OTCQX: VXRT) updated its BARDA funding award for the Phase 2b COVID-19 oral pill vaccine trial. Total available trial funding is now about $345 million, down roughly $116 million after an earlier BARDA partial termination and ~50% participant reduction.
The latest modification releases about $29 million to complete the trial and exploratory analyses. Vaxart plans to report 12‑month data from a 400‑participant sentinel cohort in the coming weeks and from the 5,085‑participant main cohort in the first half of 2027.
Vaxart (OTCQX: VXRT) released a shareholder letter from new independent directors James Breitmeyer and Kevin Finney ahead of the July 16, 2026 Annual Meeting.
The directors urge stockholders to vote “FOR” all six Vaxart nominees on the WHITE proxy card, emphasizing board continuity, oversight of Phase 2b COVID-19 work, the Dynavax funding partnership, and responses to BARDA stop-work orders amid a dissident group’s attempt to replace half the board.
Vaxart (OTCQX: VXRT) will showcase its oral vaccine platform and strategic vision at the 2026 Taiwan Biotech Forum and BIO International Convention in San Diego.
Company leaders will discuss targeting mucosal immunity with oral tablets, which may reduce reliance on injections and cold-chain logistics.
Vaxart (OTCQX: VXRT), a clinical-stage biotech developing oral recombinant vaccines, announced participation in BTIG Infectious Disease Day 2026 on June 16, 2026.
The virtual event will feature 1x1 meetings between Vaxart management and institutional investors arranged through BTIG representatives.
Vaxart (OTCQX: VXRT) mailed a letter urging shareholders to vote “FOR” all six director nominees on the WHITE proxy card ahead of the July 16, 2026 Annual Meeting. The company highlights active BARDA-funded Phase 2b COVID-19 and norovirus programs, platform-validation efforts, and influenza development.
Vaxart reports an extended cash runway into Q2 2027 via its Dynavax partnership, a $25 million Lincoln Park Capital share purchase agreement, a 21% workforce reduction, and a headquarters relocation, and argues board continuity is important during these clinical and financial milestones.
Vaxart (OTCQX: VXRT) filed a definitive proxy statement and mailed a letter urging shareholders to vote “FOR” all six board nominees on the WHITE proxy card ahead of the July 16, 2026 annual meeting.
The company highlights experienced biotech leadership as it advances a BARDA-funded Phase 2b COVID-19 oral vaccine trial supported by a Project NextGen award valued at up to $453 million, a norovirus vaccine program, and broader pipeline work. Vaxart notes a Dynavax (now Sanofi) partnership that extends cash runway into Q2 2027 and a $25 million share purchase agreement, and stresses CEO Steve Lo’s equity-heavy pay structure as aligning his interests with shareholders.
Vaxart (OTCQX: VXRT) filed a preliminary proxy statement for its July 16, 2026 annual meeting and issued a letter urging support for its current Board. The company highlights full enrollment of its BARDA-supported Phase 2b COVID-19 oral vaccine trial, progress in norovirus and influenza programs, and actions taken to extend cash runway into Q2 2027, including a Dynavax strategic partnership, cost reductions, and a $25 million share purchase agreement.
Vaxart (OTCQX: VXRT) provided a business update and first-quarter 2026 results on May 7, 2026. Key items: topline data from a 400-person sentinel cohort in its Phase 2b COVID-19 trial is expected in Q2 2026; cash, cash equivalents, and investments were $61.0 million as of March 31, 2026 with runway into Q2 2027; revenue was $39.2 million for Q1 2026 and net income was $5.2 million. Other items: cumulative BARDA payments of $218.9 million, a share purchase agreement up to $25 million, norovirus program updates, and a May 8, 2026 stockholder fireside chat.